Gilead Sciences Inc
GILD124.700USD
-0.970-0.77%
Handelsschluss 12/26, 16:00（ET）Kurse um 15 Minuten verzögert
154.88BMarktkapitalisierung
19.15KGV TTM
mehr Informationen über Gilead Sciences Inc Unternehmen
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
Gilead Sciences Inc Informationen
BörsenkürzelGILD
Name des UnternehmensGilead Sciences Inc
IPO-datumJan 22, 1992
CEOO'Day (Daniel P)
Anzahl der mitarbeiter17600
WertpapierartOrdinary Share
GeschäftsjahresendeJan 22
Addresse333 Lakeside Dr
StadtFOSTER CITY
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94404-1147
Telefon16505743000
Websitehttps://www.gilead.com/
BörsenkürzelGILD
IPO-datumJan 22, 1992
CEOO'Day (Daniel P)
Führungskräfte von Gilead Sciences Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
79.97K
-3.62%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+6.18%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+14.82%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Ms. Erin Burkhart
Ms. Erin Burkhart
Senior Vice President, Principal Accounting Officer, Controller
Senior Vice President, Principal Accounting Officer, Controller
--
--
Dr. Dietmar P. Berger, M.D., Ph.D.
Dr. Dietmar P. Berger, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Dr. Ted W. Love, M.D.
Dr. Ted W. Love, M.D.
Independent Director
Independent Director
--
--
Mr. Javier J. Rodriguez
Mr. Javier J. Rodriguez
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
79.97K
-3.62%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
26.06K
+6.18%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
11.75K
+14.82%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Ms. Erin Burkhart
Ms. Erin Burkhart
Senior Vice President, Principal Accounting Officer, Controller
Senior Vice President, Principal Accounting Officer, Controller
--
--
Dr. Dietmar P. Berger, M.D., Ph.D.
Dr. Dietmar P. Berger, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
FY2015
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Biktarvy
3.53B
49.84%
Descovy
653.00M
9.22%
Yescarta
393.00M
5.55%
Genvoya
378.00M
5.34%
Trodelvy
364.00M
5.14%
Andere
1.76B
24.91%
Nach RegionUSD
Name
Umsatz
Anteil
United States
5.00B
70.59%
Europe
1.17B
16.51%
Other Locations
792.00M
11.18%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Biktarvy
3.53B
49.84%
Descovy
653.00M
9.22%
Yescarta
393.00M
5.55%
Genvoya
378.00M
5.34%
Trodelvy
364.00M
5.14%
Andere
1.76B
24.91%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.54%
BlackRock Institutional Trust Company, N.A.
5.86%
State Street Investment Management (US)
4.76%
Fidelity Management & Research Company LLC
4.34%
Capital World Investors
3.64%
Andere
71.86%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.54%
BlackRock Institutional Trust Company, N.A.
5.86%
State Street Investment Management (US)
4.76%
Fidelity Management & Research Company LLC
4.34%
Capital World Investors
3.64%
Andere
71.86%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
54.42%
Investment Advisor/Hedge Fund
25.61%
Pension Fund
2.86%
Research Firm
2.81%
Hedge Fund
2.00%
Bank and Trust
1.90%
Sovereign Wealth Fund
1.73%
Insurance Company
0.15%
Venture Capital
0.10%
Andere
8.41%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
3433
1.13B
91.16%
+23.58K
2025Q2
3388
1.12B
90.01%
-12.02M
2025Q1
3442
1.12B
90.14%
-10.49M
2024Q4
3313
1.12B
90.13%
+4.63M
2024Q3
3207
1.10B
88.48%
-11.56M
2024Q2
3188
1.10B
88.24%
-14.37M
2024Q1
3196
1.10B
88.13%
-22.04M
2023Q4
3252
1.11B
88.75%
-8.79M
2023Q3
3190
1.10B
88.14%
-23.58M
2023Q2
3196
1.10B
88.02%
-11.22M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
118.78M
9.57%
+1.87M
+1.60%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
70.80M
5.71%
+138.89K
+0.20%
Jun 30, 2025
State Street Investment Management (US)
59.19M
4.77%
-335.51K
-0.56%
Jun 30, 2025
Fidelity Management & Research Company LLC
53.76M
4.33%
+2.55M
+4.98%
Jun 30, 2025
Capital World Investors
46.30M
3.73%
-7.24M
-13.53%
Jun 30, 2025
Dodge & Cox
30.82M
2.48%
-1.88M
-5.74%
Jun 30, 2025
Capital Research Global Investors
31.10M
2.51%
-23.51M
-43.06%
Jun 30, 2025
Geode Capital Management, L.L.C.
29.21M
2.35%
+727.51K
+2.55%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
25.46M
2.05%
-89.95K
-0.35%
Aug 31, 2025
Wellington Management Company, LLP
37.53M
3.02%
+10.17M
+37.18%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Fri, Dec 5
Aktualisiert: Fri, Dec 5
Name
Anteil
VanEck Biotech ETF
12.54%
ProShares Ultra Nasdaq Biotechnology
8.6%
Invesco Nasdaq Biotechnology ETF
8.54%
iShares Biotechnology ETF
7.24%
Simplify Health Care ETF
7.21%
Invesco Pharmaceuticals ETF
5.11%
Invesco Biotechnology & Genome ETF
5.08%
ProShares Nasdaq-100 Dorsey Wright Momentum ETF
4.62%
First Trust NASDAQ Pharmaceuticals ETF
4.12%
Tema Heart & Health ETF
3.95%
Mehr Anzeigen
VanEck Biotech ETF
Anteil12.54%
ProShares Ultra Nasdaq Biotechnology
Anteil8.6%
Invesco Nasdaq Biotechnology ETF
Anteil8.54%
iShares Biotechnology ETF
Anteil7.24%
Simplify Health Care ETF
Anteil7.21%
Invesco Pharmaceuticals ETF
Anteil5.11%
Invesco Biotechnology & Genome ETF
Anteil5.08%
ProShares Nasdaq-100 Dorsey Wright Momentum ETF
Anteil4.62%
First Trust NASDAQ Pharmaceuticals ETF
Anteil4.12%
Tema Heart & Health ETF
Anteil3.95%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
18.49B
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Oct 30, 2025
GILD.NB Final Cash Dividend of gross USD 0.79 paid on Dec 30, 2025 going ex on Dec 15, 2025
Dec 15, 2025
Dec 30, 2025
Dec 15, 2025
Aug 07, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Sep 29, 2025 going ex on Sep 15, 2025
Sep 15, 2025
Sep 29, 2025
Sep 15, 2025
Apr 24, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Jun 27, 2025 going ex on Jun 13, 2025
Jun 13, 2025
Jun 27, 2025
Jun 13, 2025
Feb 11, 2025
GILD.NB Interim Cash Dividend of gross USD 0.79 paid on Mar 28, 2025 going ex on Mar 14, 2025
Mar 14, 2025
Mar 28, 2025
Mar 14, 2025
Nov 12, 2024
GILD.NB Final Cash Dividend of gross USD 0.77 paid on Dec 30, 2024 going ex on Dec 13, 2024
Dec 13, 2024
Dec 30, 2024
Dec 13, 2024
Aug 13, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Sep 27, 2024 going ex on Sep 13, 2024
Sep 13, 2024
Sep 27, 2024
Sep 13, 2024
Apr 26, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Jun 27, 2024 going ex on Jun 14, 2024
Jun 14, 2024
Jun 27, 2024
Jun 14, 2024
Feb 06, 2024
GILD.NB Interim Cash Dividend of gross USD 0.77 paid on Mar 28, 2024 going ex on Mar 14, 2024
Mar 15, 2024
Mar 28, 2024
Mar 14, 2024
Nov 08, 2023
GILD.NB Final Cash Dividend of gross USD 0.75 paid on Dec 28, 2023 going ex on Dec 14, 2023
Dec 15, 2023
Dec 28, 2023
Dec 14, 2023
Aug 07, 2023
GILD.NB Interim Cash Dividend of gross USD 0.75 paid on Sep 28, 2023 going ex on Sep 14, 2023
Sep 15, 2023
Sep 28, 2023
Sep 14, 2023
Mehr Anzeigen
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Gilead Sciences Inc?
Die fünf größten Anteilseigner von Gilead Sciences Inc sind:
The Vanguard Group, Inc. hält 118.78M Aktien, was 9.57% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 70.80M Aktien, was 5.71% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 59.19M Aktien, was 4.77% der Gesamtaktien entspricht.
Fidelity Management & Research Company LLC hält 53.76M Aktien, was 4.33% der Gesamtaktien entspricht.
Capital World Investors hält 46.30M Aktien, was 3.73% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 118.78M Aktien, was 9.57% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 70.80M Aktien, was 5.71% der Gesamtaktien entspricht.
State Street Investment Management (US) hält 59.19M Aktien, was 4.77% der Gesamtaktien entspricht.
Fidelity Management & Research Company LLC hält 53.76M Aktien, was 4.33% der Gesamtaktien entspricht.
Capital World Investors hält 46.30M Aktien, was 3.73% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Gilead Sciences Inc?
Die drei wichtigsten Anteilseigner-Typen von Gilead Sciences Inc sind:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Wie viele Institutionen halten Anteile an Gilead Sciences Inc (GILD)?
Mit Stand vom 2025Q3 halten 3433 Institutionen Anteile an Gilead Sciences Inc, mit einem Gesamtmarktwert von etwa 1.13B, was 91.16% der Gesamtanteile entspricht. Im Vergleich zum 2025Q2 ist der institutionelle Aktienbesitz um 1.15% gestiegen.
Was ist die größte Einnahmequelle von Gilead Sciences Inc?
Am FY2025Q2 erzielte das Geschäft mit Biktarvy für Gilead Sciences Inc den höchsten Umsatz in Höhe von 3.53B, was 49.84% des Gesamtumsatzes entspricht.
